Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Non-small cell lung cancer consultation

The National Institute for Health and Care Excellence (NICE) is consulting on its review of the use of erlotinib (Tarceva; Roche) and gefitinib (Iressa; AstraZeneca) for the treatment of non-small cell lung cancer that has progressed after prior chemotherapy. The new draft guidance provisionally recommends erlotinib as a treatment option for people with non-small-cell lung cancer that has progressed after prior chemotherapy in specific circumstances – but does not recommend gefitinib. The draft guidance is open for comment until 28 August 2014. Further information can be found on the NICE website, using the technology appraisal (TA) references TA162 and TA175. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066133

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.